| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $11.8M | -70.1% |
| SG&A Expense | $44.2M | -7.0% |
| Operating Income | -$73.5M | +53.8% |
| Pre-tax Income | -$74.1M | +52.5% |
| Net Income | -$74.1M | +52.5% |
| EPS (Basic) | -$11.39 | +52.5% |
| EPS (Diluted) | -$11.39 | +52.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $8.8M | -4.2% |
| Current Assets | $124.5M | -22.6% |
| Total Assets | $263.6M | -19.1% |
| Current Liabilities | $7.9M | -25.2% |
| Total Liabilities | $94.1M | -5.7% |
| Stockholders' Equity | $169.4M | -25.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$55.7M | +32.1% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | $54.0M | +31.2% |
| Financing Cash Flow | $1.8M | -78.3% |
| Free Cash Flow | -$55.7M | +45.8% |